Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.”In the company’s words, NCT06220864 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor, Pancreatic Cancer, Pancreatic Acinar Carcinoma
- Main trialPhase 1
- “This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.”In the company’s words, NCT06220864 on ClinicalTrials.gov
- Other names
- PARP inhibitor
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 1 Jun 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2027 | SNV1521 in Participants With Advanced Solid Tumors | |
| Phase 1Recruiting | 1 Jun 2029 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026